ophthalmologytimes2d
Outlook Therapeutics completes analysis of 12-week safety and efficacy results of NORSE EIGHT
The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics ...
manilatimes3d
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
Outlook Therapeutics, Inc. (Outlook Therapeutics, or the Company) (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom for the ...
ophthalmologytimes4d
Snowmass Retina and Eye 2025: Ronald Frenkel, MD, previews interactive learning and innovation amid winter fun
Dr. Frenkel highlights a comprehensive program that covers the latest breakthroughs in glaucoma and cataract surgery to in-depth discussions on AI, retinal treatments, and new drug-delivery platforms, ...
Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge
Aging Population and Pipeline Launches Fuel Rapid Growth in Ophthalmic Pharma MarketDublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Ophthalmic Drugs Market Report 2025-2035" has been added to ...